Hereditary Cancer Syndromes > BRIP1, BARD1, RAD51C, RAD51D

Cancer Risks

Cancer Risks

Cancer Risks

Cancer Risks

Associated Syndrome

Medical Management

BRIP1 Gene Cancer Risk Management Table

CANCER TYPE PROCEDURE AGE TO BEGIN FREQUENCY
Ovarian Consider bilateral salpingo-oophorectomy (BSO). 45 to 50 years, or earlier if there is a family history of ovarian cancer at a younger age NA
  Other than consideration of BSO, currently there are no specific medical management recommendations for ovarian cancer risk in mutation carriers. However, the increase in risk may warrant consideration of individualized ovarian cancer risk-reduction strategies using other currently available options, such as surveillance and the use of risk-reducing agents. Individualized NA

BARD1 Gene Cancer Risk Management Table

CANCER TYPE PROCEDURE AGE TO BEGIN FREQUENCY
Female Breast Currently there are no specific medical management guidelines for breast cancer risk in mutation carriers. However, the possibility of an increased risk for breast cancer warrants consideration of individualized breast cancer risk-reduction strategies, such as the modification of standard population screening recommendations by starting screening at younger ages and/or performing screenings at greater frequency. Individualized NA

Medical Management

RAD51C Gene Cancer Risk Management Table

CANCER TYPE PROCEDURE AGE TO BEGIN FREQUENCY
Ovarian Consider bilateral salpingo-oophorectomy (BSO). 45 to 50 years, or earlier if there is a family history of ovarian cancer at a younger age NA
  Other than consideration of BSO, currently there are no specific medical management recommendations for ovarian cancer risk in mutation carriers. However, the increase in risk may warrant consideration of individualized ovarian cancer risk reduction strategies using other currently available options, such as surveillance and the use of risk reducing agents. Individualized NA

RAD51D Gene Cancer Risk Management Table

CANCER TYPE PROCEDURE AGE TO BEGIN FREQUENCY
Ovarian Consider bilateral salpingo-oophorectomy (BSO). 45 to 50 years, or earlier if there is a family history of ovarian cancer at a younger age NA
  Other than consideration of BSO, currently there are no specific medical management recommendations for ovarian cancer risk in mutation carriers. However, the increase in risk may warrant consideration of individualized ovarian cancer risk-reduction strategies using other currently available options, such as surveillance and the use of risk-reducing agents. Individualized NA

Unique Challenge and Issues